The stock of INC Research Holdings Inc (NASDAQ:INCR) is a huge mover today! About 770,439 shares traded hands or 59.82% up from the average. INC Research Holdings Inc (NASDAQ:INCR) has risen 1.25% since March 29, 2016 and is uptrending. It has underperformed by 2.23% the S&P500.
The move comes after 9 months positive chart setup for the $2.44 billion company. It was reported on Oct, 31 by Barchart.com. We have $70.76 PT which if reached, will make NASDAQ:INCR worth $1.29 billion more.
Analysts await INC Research Holdings Inc (NASDAQ:INCR) to report earnings on November, 3. They expect $0.58 EPS, up 3.57% or $0.02 from last year’s $0.56 per share. INCR’s profit will be $30.60M for 19.94 P/E if the $0.58 EPS becomes a reality. After $0.57 actual EPS reported by INC Research Holdings Inc for the previous quarter, Wall Street now forecasts 1.75% EPS growth.
INC Research Holdings Inc (NASDAQ:INCR) Ratings Coverage
Out of 8 analysts covering INC Research Holdings (NASDAQ:INCR), 6 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 75% are positive. INC Research Holdings has been the topic of 11 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The rating was downgraded by Robert W. Baird to “Neutral” on Tuesday, May 3. Goldman Sachs maintained the stock with “Buy” rating in Friday, August 12 report. The firm earned “Buy” rating on Thursday, November 19 by SunTrust. The rating was reinitiated by Credit Suisse on Friday, August 14 with “Outperform”. The rating was maintained by Jefferies on Wednesday, August 17 with “Buy”. The rating was initiated by Suntrust Robinson with “Buy” on Thursday, November 19. Credit Suisse initiated INC Research Holdings Inc (NASDAQ:INCR) rating on Tuesday, June 21. Credit Suisse has “Outperform” rating and $51 price target. JP Morgan initiated INC Research Holdings Inc (NASDAQ:INCR) rating on Thursday, March 24. JP Morgan has “Overweight” rating and $47 price target. As per Monday, April 18, the company rating was maintained by Avondale. Jefferies upgraded INC Research Holdings Inc (NASDAQ:INCR) rating on Tuesday, September 1. Jefferies has “Buy” rating and $51 price target.
According to Zacks Investment Research, “INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina.”
Insitutional Activity: The institutional sentiment decreased to 1.27 in 2016 Q2. Its down 0.21, from 1.48 in 2016Q1. The ratio fall, as 28 funds sold all INC Research Holdings Inc shares owned while 62 reduced positions. 35 funds bought stakes while 79 increased positions. They now own 47.68 million shares or 7.23% more from 44.47 million shares in 2016Q1.
Kornitzer Capital Incorporated Ks accumulated 242,120 shares or 0.17% of the stock. Northern holds 0.01% of its portfolio in INC Research Holdings Inc (NASDAQ:INCR) for 482,111 shares. Blackrock Invest Mgmt Ltd Limited Liability Company holds 0.01% of its portfolio in INC Research Holdings Inc (NASDAQ:INCR) for 154,630 shares. Turner Investments L P accumulated 0.03% or 2,800 shares. Carlyle Limited Partnership has 96,419 shares for 0.06% of their US portfolio. Convergence Inv Partners Limited Com accumulated 0.22% or 42,720 shares. Lpl Fincl Ltd Liability Corp holds 6,254 shares or 0% of its portfolio. Acadian Asset Mgmt Limited has 2.09 million shares for 0.41% of their US portfolio. Numeric Invsts Llc has 0.13% invested in the company for 392,787 shares. Tudor Corp Et Al holds 0.03% or 33,535 shares in its portfolio. Quantbot Technologies Limited Partnership owns 9,441 shares or 0.04% of their US portfolio. The Switzerland-based Swiss Natl Bank has invested 0% in INC Research Holdings Inc (NASDAQ:INCR). Cantab Cap Prtnrs Llp accumulated 19,688 shares or 0% of the stock. The New York-based Clearbridge Invs Ltd Liability Company has invested 0.05% in INC Research Holdings Inc (NASDAQ:INCR). Jennison Associate Ltd Liability Company reported 21,882 shares or 0% of all its holdings.
More important recent INC Research Holdings Inc (NASDAQ:INCR) news were published by: Globenewswire.com which released: “INC Research Announces Updates to Board of Directors” on October 31, 2016, also Streetinsider.com published article titled: “INC Research Holdings (INCR) Tops Q3 EPS by 1c, Bumps FY16 EPS Outlook”, Reuters.com published: “BRIEF-INC Research Holdings Q3 earnings per share $0.49” on October 31, 2016. More interesting news about INC Research Holdings Inc (NASDAQ:INCR) was released by: Globenewswire.com and their article: “INC Research Receives 2016 Frost & Sullivan Asia Pacific Contract Research …” with publication date: October 24, 2016.
INCR Company Profile
INC Research Holdings, Inc., incorporated on August 13, 2010, is a global contract research organization (CRO). The Firm is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Firm operates through two divisions: Clinical Development Services and Phase I Services. The Firm provides a range of services, which supports the entire drug development process from Phase I to Phase IV and it also offer its clients an integrated suite of investigative site support and clinical development services. The Firm offers the services across all therapeutic areas with a primary focus on Phase I to Phase IV clinical trials. The Firm provides total biopharmaceutical program development while also providing discrete services for any part of a trial. The Company’s Clinical Development Services offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist clients with their drug development process, quality assurance audits and specialized consulting services. Phase I Services focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.